Akamai Technologies Inc (AKAM) Stock Price & Analysis
Akamai Technologies Inc (AKAM) fell 2.86% to USD 137.81 as of June 10, 2026 at 00:27 UTC, according to Nexqual real-time market data.
AKAM last closed at USD 141.87; the session ranged USD 132.58–142.64 on volume of 4,065,793 shares. Market capitalization is $20.04B, with a 52-week range of USD 69.78–165.45 (NMS). Source: Nexqual, June 10, 2026 at 00:27 UTC.
Key Statistics (as of June 10, 2026 at 00:27 UTC)
| Price | USD 137.81 |
|---|---|
| Change | ▼ 2.86% (down) |
| Previous Close | USD 141.87 |
| Open | USD 141.96 |
| Day Range | USD 132.58 – 142.64 |
| 52-Week Range | USD 69.78 – 165.45 |
| Volume | 4,065,793 shares |
| Market Cap | $20.04B |
| Exchange | NMS |
Technical Analysis (AKAM)
Nexqual's technical model rates AKAM "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 50.26 (neutral) |
| vs SMA50 | Above (USD 124.22) |
| MACD | 6.47 (positive) |
Analyst Ratings (AKAM)
Wall Street analysts rate AKAM "Buy" based on 23 analysts, with a mean price target of USD 159.3 (range USD 87–195), per Nexqual as of June 10, 2026 at 00:27 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 23 |
| Mean Target | USD 159.3 |
| High Target | USD 195 |
| Low Target | USD 87 |
| Buy / Hold / Sell | 14 / 8 / 3 |
Earnings (AKAM)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 1.58 |
| Revenue Estimate | $1.09B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.61 vs est 1.6 ▲ beat |
| 2025-12-31 | USD 1.84 vs est 1.75 ▲ beat |
| 2025-09-30 | USD 1.86 vs est 1.64 ▲ beat |
| 2025-06-30 | USD 1.73 vs est 1.53 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financials & Fundamentals (AKAM)
| Total Revenue | $4.27B |
|---|---|
| Revenue Growth (YoY) | +5.80% |
| Gross Margin | +58.28% |
| Operating Margin | +10.61% |
| Profit Margin | +10.20% |
| ROE | +9.17% |
| Debt / Equity | 119.53 |
| Current Ratio | 2.06 |
| Total Cash | $930.44M |
| Total Debt | $5.87B |
| Free Cash Flow | $700.72M |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Financial Health Score (AKAM)
Nexqual rates Akamai Technologies Inc's overall financial health "Solid" across five dimensions, as of June 10, 2026 at 00:27 UTC.
| Growth | Solid — Revenue +5% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 58%, operating 11% |
| Balance Sheet | Mixed — $930M cash vs $5.87B debt |
| Cash Flow | Strong — FCF $701M, 17% margin |
| Efficiency | Mixed — ROE 9%, ROA 3.4% |
Ownership (AKAM)
| Insider Ownership | +2.10% |
|---|---|
| Institutional Ownership | +111.53% |
| Shares Outstanding | 145.39M |
| Float | 142.05M |
| Short % of Float | +14.68% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
Leadership (AKAM)
Akamai Technologies Inc is led by F. Thomson Leighton (age 68), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 00:27 UTC.
| Co-Founder, CEO, President & Director | F. Thomson Leighton (age 68) |
|---|---|
| Executive VP, CFO & Treasurer | Edward J. McGowan (age 54) |
| COO & GM of Cloud Technology Group | Adam Karon (age 53) |
| Executive Vice President of Global Sales & Services | Paul Joseph (age 51) |
| Executive VP & CTO | Robert Blumofe (age 60) |
Major Backers & Investors (AKAM)
Notable institutional backers of Akamai Technologies Inc include Capital Group, First Trust Advisors LP, GROWTH FUND OF AMERICA, according to Nexqual as of June 10, 2026 at 00:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 4.65% |
| First Trust Advisors LP | 3.29% |
| GROWTH FUND OF AMERICA | 2.48% |
| Invesco | 2.39% |
| Point72 Asset Management, L.P. | 2.27% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.6% |
| BlackRock | 8.44% |
| State Street | 3.79% |
| Geode Capital | 2.83% |
| Dimensional Fund Advisors | 2.38% |
Source: Nexqual, June 10, 2026 at 00:27 UTC.
From Akamai Technologies Inc's Latest SEC 10-K Filing (filed 2026-02-20)
Key Strengths & Strategy (as disclosed to the SEC)
- Our portfolio encompasses mature, market-leading security products including web application firewall ("WAF"), bot management, distributed denial-of-service ("DDoS") protection and domain name system ("DNS") security, complemented by fast-growing solutions in application programming interface ("API") security and network segmentation.
- The Akamai App Platform is built on top of the cloud native Kubernetes technology Otomi, which Akamai acquired from Red Kubes Holding B.V. and its subsidiary.
- Sales, Services and Marketing We market and sell our solutions globally through our field sales and services organization and through many channel partners, including adidas, AHEAD, Avant, BV Tech, Carahsoft, CPD, Deloitte, Deutsche Telecom, Doyen, Guidepoint, Kyndryl, LevelBlue, Macnica, Microsoft Azure, Netpoleon, Oplium, Optiv, Presidio, SHI, Telefonica Group, Trace3 and WWT.
- We believe that a focus on employee choice makes us a more attractive employer, increases productivity, enables us to recruit from a broader and more varied pool of applicants and presents additional growth and development opportunities for our employees.
Partnerships
- Cloud Infrastructure Services, which represent the majority of Akamai's strategic investment and differentiation, consist of compute, storage, cloud-native and networking solutions, along with the Akamai EdgeWorkers serverless products and partner solutions running on our cloud platform.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| FFIV | F5, Inc. | USD 395.23 | ▲ 0.48% |
| NTAP | NetApp, Inc. | USD 165 | ▼ 1.22% |
| VRSN | VeriSign, Inc. | USD 283.89 | ▼ 3.74% |
| ADSK | Autodesk, Inc. | USD 224.08 | ▼ 2.56% |
| CHKP | Check Point Software Technologi | USD 127.43 | ▼ 6.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:27 UTC. This page is informational and not investment advice.